National Health (Highly specialised drugs program for hospitals) Special Arrangement Amendment Instrument 2013 (No. 9) (No. PB 92 of 2013)

Link to law: https://www.comlaw.gov.au/Details/F2013L02191

Subscribe to a Global-Regulation Premium Membership Today!

Key Benefits:

Subscribe Now
 
PB 92 of 2013
National Health (Highly specialised drugs program for hospitals) Special Arrangement Amendment Instrument 2013 (No. 9)
 
National Health Act 1953
___________________________________________________________________________
 
 
I, KIM BESSELL, Assistant Secretary, Pharmaceutical Access Branch, Pharmaceutical Benefits Division, Department of Health, delegate of the Minister for Health, make this Amendment Instrument under subsections 100(1) and 100(2) of the
National Health Act 1953.
Dated   20 December 2013
 
 
 
 
 
 
 
 
 
 
 
 
 
 
KIM BESSELL
Assistant Secretary
Pharmaceutical Access Branch
Pharmaceutical Benefits Division
Department of Health
___________________________________________________________________________
 
 
1       Name of Instrument
 
(1)                This Instrument is the National Health (Highly specialised drugs program for hospitals) Special Arrangement Amendment Instrument 2013 (No.9).
 
(2)                This Instrument may also be cited as PB 92 of 2013.
 
2              Commencement
This Instrument commences on 1 January 2014.
3              Amendments to PB 116 of 2010
Schedule 1 amends the National Health (Highly specialised drugs program for hospitals) Special Arrangement 2010 (PB 116 of 2010).
 
 
Schedule 1       Amendments
Section 3
[1]     Schedule 1, entry for Clozapine in the form Tablet 25 mg with the manner of administration Oral, brand Clopine 25
          Omit from the column headed ‘Circumstances’: C1826, C1827, C3326, C3327            Substitute: C4371, C4411
[2]     Schedule 1, entry for Clozapine in the form Tablet 25 mg with the manner of administration Oral, brand Clozaril 25
          Omit from the column headed ‘Circumstances’: C1826, C1827, C3326, C3327            Substitute: C4371, C4411
[3]     Schedule 1, entry for Clozapine in the form Tablet 50 mg with the manner of administration Oral, brand Clopine 50
          Omit from the column headed ‘Circumstances’: C1826, C1827, C3326, C3327            Substitute: C4371, C4411
[4]     Schedule 1, entry for Clozapine in the form Tablet 100 mg with the manner of administration Oral, brand Clopine 100
          Omit from the column headed ‘Circumstances’: C1826, C1827, C3326, C3327            Substitute: C4371, C4411
[5]     Schedule 1, entry for Clozapine in the form Tablet 100 mg with the manner of administration Oral, brand Clozaril 100
          Omit from the column headed ‘Circumstances’: C1826, C1827, C3326, C3327            Substitute: C4371, C4411
[6]     Schedule 1, entry for Clozapine in the form Tablet 200 mg with the manner of administration Oral, brand Clopine 200
          Omit from the column headed ‘Circumstances’: C1826, C1827, C3326, C3327            Substitute: C4371, C4411
[7]     Schedule 1, entry for Clozapine in the form Oral Liquid 50 mg per mL, 100 mL with the manner of administration Oral, brand Clopine Suspension
          Omit from the column headed ‘Circumstances’: C1826, C1827, C3326, C3327            Substitute: C4371, C4411
[8]     Schedule 1, entry for Ganciclovir in the form intravitreal implant 4.5 mg with manner of administration implantation, brand Vitrasert            
Omit
 
[9]     Schedule 1, entry for Pamidronic Acid in the form injection containing 4 vials powder for I.V. infusion containing disodium pamidronate 15 mg and 4 ampoules solvent 5 mL with manner of administration injection, brand
Aredia 15 mg
          Omit
[10]   Schedule 3, entry for Clozapine
          Omit
[11]   Schedule 3, entry for Clozapine, after entry for Clarithromycin, Circumstance Code C3325
          Insert:
Clozapine
C4371
 
Where the patient is receiving treatment at/from a private hospital
Schizophrenia
Patient must be non-responsive to other neuroleptic agents; OR
Patient must be intolerant of other neuroleptic agents.
A medical practitioner should request a quantity sufficient for up to one month's supply. Up to 5 repeats will be authorised.

Compliance with Written and Telephone Authority Required procedures
 

 
C4411
 
Where the patient is receiving treatment at/from a public hospital
Schizophrenia
Patient must be non-responsive to other neuroleptic agents; OR
Patient must be intolerant of other neuroleptic agents.
A medical practitioner should request a quantity sufficient for up to one month's supply. Up to 5 repeats will be authorised.
Compliance with Written and Telephone Authority Required procedures - Streamlined Authority Code 4411